AOP-Wiki

API

All KERs

Showing 151 to 175 of 3158 KERs

ID	Upstream Event	Downstream Event	Creation Date	Last Updated	AOPs

565	564: Abnormal, Roll change within caste	565: Reduced, Brood care	Nov 29, 2016	Dec 3, 2016	3 AOPs 82: Abnormal role change in worker caste contributes to reduced brood care and leads to colony loss/failure 90: Nicotinic acetylcholine receptor activation contributes to abnormal roll change within the worker bee caste leading to colony loss/failure 2 78: Nicotinic acetylcholine receptor activation contributes to abnormal role change within the worker bee caste leading to colony death failure 1
566	565: Reduced, Brood care	566: impaired, Larval development	Nov 29, 2016	Dec 3, 2016	3 AOPs 82: Abnormal role change in worker caste contributes to reduced brood care and leads to colony loss/failure 90: Nicotinic acetylcholine receptor activation contributes to abnormal roll change within the worker bee caste leading to colony loss/failure 2 78: Nicotinic acetylcholine receptor activation contributes to abnormal role change within the worker bee caste leading to colony death failure 1
585	584: Inhibition, sodium channel	585: Decreased, Sodium conductance 1	Nov 29, 2016	Dec 3, 2016	3 AOPs 91: Sodium channel inhibition leading to reduced survival 93: sodium channel inhibition leading to increased predation 94: Sodium channel inhibition leading to congenital malformations
586	585: Decreased, Sodium conductance 1	586: Reduced, swimming speed	Nov 29, 2016	Dec 3, 2016	3 AOPs 91: Sodium channel inhibition leading to reduced survival 93: sodium channel inhibition leading to increased predation 95: Ether-a-go-go (ERG) voltage-gated potassium channel inhibition leading to reduced survival
588	586: Reduced, swimming speed	588: Increased, predation	Nov 29, 2016	Dec 3, 2016	3 AOPs 91: Sodium channel inhibition leading to reduced survival 95: Ether-a-go-go (ERG) voltage-gated potassium channel inhibition leading to reduced survival 93: sodium channel inhibition leading to increased predation
658	559: Activation, Nicotinic acetylcholine receptor	663: Desensitization, Nicotinic acetylcholine receptor	Nov 29, 2016	Jun 7, 2018	3 AOPs 89: Nicotinic acetylcholine receptor activation followed by desensitization contributes to abnormal foraging and directly leads to colony loss/failure 88: Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony loss/failure via abnormal role change within caste 90: Nicotinic acetylcholine receptor activation contributes to abnormal roll change within the worker bee caste leading to colony loss/failure 2
742	739: Increase, Hypertrophy and proliferation (follicular cell)	740: Increase, Hyperplasia (follicular cells)	Nov 29, 2016	Dec 3, 2016	3 AOPs 110: Inhibition of iodide pump activity leading to follicular cell adenomas and carcinomas (in rat and mouse) 119: Inhibition of thyroid peroxidase leading to follicular cell adenomas and carcinomas (in rat and mouse) 162: Enhanced hepatic clearance of thyroid hormones leading to thyroid follicular cell adenomas and carcinomas in the rat and mouse
743	740: Increase, Hyperplasia (follicular cells)	741: Increase, Adenomas/carcinomas (follicular cell)	Nov 29, 2016	Dec 3, 2016	3 AOPs 110: Inhibition of iodide pump activity leading to follicular cell adenomas and carcinomas (in rat and mouse) 119: Inhibition of thyroid peroxidase leading to follicular cell adenomas and carcinomas (in rat and mouse) 162: Enhanced hepatic clearance of thyroid hormones leading to thyroid follicular cell adenomas and carcinomas in the rat and mouse
774	774: Increase, Preneoplastic foci (hepatocytes)	719: Increase, hepatocellular adenomas and carcinomas	Nov 29, 2016	Feb 15, 2017	3 AOPs 107: Constitutive androstane receptor activation leading to hepatocellular adenomas and carcinomas in the mouse and the rat 117: Androgen receptor activation leading to hepatocellular adenomas and carcinomas (in mouse and rat) 118: Chronic cytotoxicity leading to hepatocellular adenomas and carcinomas (in mouse and rat)
933	888: Binding of inhibitor, NADH-ubiquinone oxidoreductase (complex I)	887: Inhibition, NADH-ubiquinone oxidoreductase (complex I)	Nov 29, 2016	Aug 25, 2017	3 AOPs 3: Inhibition of the mitochondrial complex I of nigro-striatal neurons leads to parkinsonian motor deficits 276: Inhibition of complex I of the electron transport chain leading to chemical induced Fanconi syndrome 273: Mitochondrial complex inhibition leading to liver injury
2811	1392: Increase, Oxidative Stress	1635: Increase, DNA strand breaks	Dec 16, 2022	Jul 29, 2024	3 AOPs 478: Deposition of energy leading to occurrence of cataracts 483: Deposition of Energy Leading to Learning and Memory Impairment 470: Deposition of energy leads to abnormal vascular remodeling
2820	1614: Decrease, AR activation	1688: AGD, decreased	Dec 22, 2022	Feb 4, 2026	3 AOPs 305: 5α-reductase inhibition leading to short anogenital distance (AGD) in male (mammalian) offspring 306: Androgen receptor (AR) antagonism leading to short anogenital distance (AGD) in male (mammalian) offspring 307: Decreased testosterone synthesis leading to short anogenital distance (AGD) in male (mammalian) offspring
2824	1532: Decrease, Cardiac contractility	1535: Heart failure	Jan 5, 2023	Jan 5, 2023	3 AOPs 553: Inhibition of Voltage-gated sodium channels (Na⁺ channels) leading to heart failure 556: Decreased Na/K ATPase activity leading to heart failure 558: Phosphodiesterase inhibition leading to heart failure
2828	1614: Decrease, AR activation	2082: Hypospadias	Jan 11, 2023	Mar 20, 2026	3 AOPs 477: Androgen receptor (AR) antagonism leading to hypospadias in male (mammalian) offspring 570: Decreased testosterone synthesis leading to hypospadias in male (mammalian) offspring 571: 5α-reductase inhibition leading to hypospadias in male (mammalian) offspring
3635	179: Decrease, Fatty acid β-oxidation	1771: Decrease, ATP pool	Sep 8, 2025	Sep 8, 2025	3 AOPs 599: Excessive reactive oxygen species leading to growth inhibition via fatty acid oxidation and cell injury/death 600: Excessive reactive oxygen species leading to growth inhibition via fatty acid oxidation and reduced cell growth 601: Excessive reactive oxygen species leading to growth inhibition via fatty acid oxidation and reduced cell proliferation
3634	1767: Increase, Protein oxidation	179: Decrease, Fatty acid β-oxidation	Sep 8, 2025	Sep 8, 2025	3 AOPs 599: Excessive reactive oxygen species leading to growth inhibition via fatty acid oxidation and cell injury/death 600: Excessive reactive oxygen species leading to growth inhibition via fatty acid oxidation and reduced cell growth 601: Excessive reactive oxygen species leading to growth inhibition via fatty acid oxidation and reduced cell proliferation
3633	1767: Increase, Protein oxidation	1446: Decrease, Coupling of OXPHOS	Sep 8, 2025	Jun 23, 2026	3 AOPs 596: Excessive reactive oxygen species leading to growth inhibition via protein oxidation and cell injury/death 332: Reactive oxygen species leading to growth inhibition via protein oxidation and decreased cell proliferation 333: Reactive oxygen species leading to growth inhibition via protein oxidation and cell death
3639	1267: Decrease, Ecdysis motor program activity	993: Decrease, Abdominal muscle contraction	Sep 29, 2025	Sep 29, 2025	3 AOPs 4: Ecdysone receptor agonism leading to mortality via suppression of Ftz-f1 342: Ecdysone receptor hyperactivation leading to mortality via mis-timed activation of nuclear receptor cascade 343: Ecdysone receptor antagonism leading to mortality via mis-timed ecdysone receptor-responsive nuclear receptor cascade
3679	2383: Increase, Hemopericardium	947: Increase, Early Life Stage Mortality	Oct 30, 2025	Oct 30, 2025	3 AOPs 612: Peroxisome proliferator-activated receptor alpha activation leading to early life stage mortality via reduced adenosine triphosphate 613: Peroxisome proliferator-activated receptor alpha activation leading to early life stage mortality via increased reactive oxygen species production 614: Peroxisome proliferator-activated receptor alpha activation leading to early life stage mortality via reduced vascular endothelial growth factor
3740	122: Increase, GR activation	1306: Increase, De novo lipogenesis	Feb 12, 2026	Feb 12, 2026	3 AOPs 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress
3738	122: Increase, GR activation	2119: Increase, Insulin resistance	Feb 12, 2026	Feb 12, 2026	3 AOPs 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress
3735	1306: Increase, De novo lipogenesis	459: Increase, Liver steatosis	Feb 11, 2026	Feb 11, 2026	3 AOPs 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress
3743	2408: Increase, Adipose lipolysis	465: Increased, FA Influx	Feb 24, 2026	Feb 24, 2026	3 AOPs 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress
3744	465: Increased, FA Influx	459: Increase, Liver steatosis	Feb 24, 2026	Feb 24, 2026	3 AOPs 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress
3721	2119: Increase, Insulin resistance	2408: Increase, Adipose lipolysis	Feb 10, 2026	Feb 10, 2026	3 AOPs 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress

Key Event Relationships (KERs)

All KERs